{"filing":{"accession_number":"0001649094-26-000045","cik":"0001649094","ticker":"PCVX","company_name":"Vaxcyte, Inc.","form":"8-K","filing_date":"2026-09-03","report_date":"2026-08-31","primary_document":"pcvx-20260831.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1649094/000164909426000045/pcvx-20260831.htm"},"events":[{"id":31627,"run_id":29032,"accession_number":"0001649094-26-000045","anchor_item_number":"5.02","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"David McAvoy was appointed as Chief Legal Officer, Chief Compliance Officer, and Corporate Secretary on August 31, 2026, bringing 30+ years of biopharmaceutical legal leadership experience from roles at Eli Lilly, Endocyte, Brickell Biotech, and Teva to support the Company through VAX-31's development and anticipated commercialization.","company_name":"Vaxcyte, Inc.","ticker":"PCVX","filing_date":"2026-09-03","form":"8-K","submitted_at":null,"items":[{"id":34561,"accession_number":"0001649094-26-000045","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"David McAvoy was appointed as Chief Legal Officer, Chief Compliance Officer, and Corporate Secretary on August 31, 2026. The press release emphasizes his extensive biopharmaceutical legal leadership (30+ years, including roles at Eli Lilly, Endocyte, Brickell Biotech, and Teva) and his critical role in supporting the Company through drug development, approval, and commercialization as VAX-31 approaches its OPUS-1 topline readout. This is a material executive appointment at a pivotal stage of the company's clinical development.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-03T20:35:31.123899+00:00","company_name":"","ticker":null,"filing_date":""},{"id":34562,"accession_number":"0001649094-26-000045","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.85,"reasoning":"The press release announces the appointments of Luis Jodar, Ph.D. as Chief Medical Officer and David McAvoy, J.D. as Chief Legal Officer, both experienced industry leaders with extensive backgrounds in vaccine development and biopharmaceutical legal leadership. While the filing also mentions narrowed guidance on VAX-31 OPUS-1 trial data timing (end of October 2026), the principal disclosed action centers on these two executive appointments at a \"pivotal time for the Company\" as it approaches a critical trial readout and potential commercialization.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-03T20:35:31.123899+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":34561,"accession_number":"0001649094-26-000045","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"David McAvoy was appointed as Chief Legal Officer, Chief Compliance Officer, and Corporate Secretary on August 31, 2026. The press release emphasizes his extensive biopharmaceutical legal leadership (30+ years, including roles at Eli Lilly, Endocyte, Brickell Biotech, and Teva) and his critical role in supporting the Company through drug development, approval, and commercialization as VAX-31 approaches its OPUS-1 topline readout. This is a material executive appointment at a pivotal stage of the company's clinical development.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-03T20:35:31.123899+00:00","company_name":"Vaxcyte, Inc.","ticker":"PCVX","filing_date":"2026-09-03"},{"id":34562,"accession_number":"0001649094-26-000045","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.85,"reasoning":"The press release announces the appointments of Luis Jodar, Ph.D. as Chief Medical Officer and David McAvoy, J.D. as Chief Legal Officer, both experienced industry leaders with extensive backgrounds in vaccine development and biopharmaceutical legal leadership. While the filing also mentions narrowed guidance on VAX-31 OPUS-1 trial data timing (end of October 2026), the principal disclosed action centers on these two executive appointments at a \"pivotal time for the Company\" as it approaches a critical trial readout and potential commercialization.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-03T20:35:31.123899+00:00","company_name":"Vaxcyte, Inc.","ticker":"PCVX","filing_date":"2026-09-03"}]}